T1	Participants 77 133	hyperphosphatemic patients with end-stage renal disease.
T2	Participants 193 241	patients receiving long-term dialysis treatment.
T3	Participants 377 422	patients with end-stage renal disease (ESRD).
T4	Participants 585 612	Chinese patients with ESRD.
T5	Participants 749 786	male and female hemodialysis patients
T6	Participants 1379 1384	n=73)
T7	Participants 1631 1636	n=30)
T8	Participants 1707 1712	n=31;
T9	Participants 2300 2327	Chinese patients with ESRD.
